Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer.
暂无分享,去创建一个
C. Obasaju | J. Jett | S. Mandrekar | S. Hillman | K. Rowland | S. Nair | A. Adjei | S. Schild | T. Fitch | Sachdev P. Thomas | Cynthia X. Ma | D. Nikcevich | H. Windschitl | Sachdev Thomas
[1] J. Sloan,et al. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors , 2005, Cancer Chemotherapy and Pharmacology.
[2] C. Obasaju,et al. Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.
[3] Miklos Pless,et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] N. Hanna. Second-line chemotherapy for non-small-cell lung cancer: recent data with pemetrexed. , 2004, Clinical lung cancer.
[5] G. Giaccone,et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] C. Gridelli,et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] L. Weissbach,et al. A phase II trial of pemetrexed in patients with metastatic renal cancer , 2003, Investigational New Drugs.
[8] L. Zelek,et al. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] A. Adjei. Preclinical and clinical studies with combinations of pemetrexed and gemcitabine. , 2002, Seminars in oncology.
[10] M. Dimopoulos,et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Clarke,et al. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[13] E. Raymond,et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck , 2001, British Journal of Cancer.
[14] P. Paoletti,et al. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. , 2001, The oncologist.
[15] D. Miles,et al. A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. , 2001, European journal of cancer.
[16] I. Vlachonikolis,et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial , 2001, The Lancet.
[17] C. Desch,et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer (NSCLC): A CALGB randomized trial of efficacy, quality of life, and cost-effectiveness , 2001 .
[18] M. Namer,et al. Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis. , 2001, Clinical breast cancer.
[19] C. Blanke,et al. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma , 2000, Cancer.
[20] J. Jett,et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[22] Suzanne F. Jones,et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation , 1999, Cancer Chemotherapy and Pharmacology.
[23] A. V. van Oosterom,et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] E. Eisenhauer,et al. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] J. Tonkinson,et al. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. , 1999, Cancer research.
[26] E. Eisenhauer,et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] P. Vasey,et al. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] R M Schultz,et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. , 1997, Cancer research.
[29] H. Burris,et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] O. Brodin,et al. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .
[31] V. Heinemann,et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. , 1995, Seminars in oncology.
[32] F. Invernizzi,et al. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. , 1994, Chest.
[33] A. Oxman,et al. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] D. Duffy,et al. Confidence Intervals for a Binomial Parameter Based on Multistage Tests , 1987 .
[35] T R Fleming,et al. One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.
[36] A. Jemal,et al. Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.
[37] A. Gregor,et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] J. Pater,et al. Second primary malignancies following the treatment of early stage ovarian cancer: update of a study by the National Cancer Institute of Canada--Clinical Trials Group (NCIC-CTG). , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[39] L. Shulman,et al. Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] D. Richel,et al. Clinical, toxicological and pharmacological aspects of gemcitabine. , 1996, Cancer treatment reviews.